24/7 Market News Snapshot 13 August, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)

August 13, 2025

DENVER, Colo., 13 August, 2025 (www.247marketnews.com) – (NASDAQ:RSLS) are discussed in this article.
ReShape Lifesciences, Inc. (RSLS) has recently demonstrated remarkable momentum in the financial markets, achieving a striking increase of over 73% during trading sessions, from an opening price of $2.08 to a current value of $3.518. This notable rise reflects substantial investor enthusiasm, evidenced by a trading volume of 6.00 million shares. The surge in RSLS stock indicates a growing optimism surrounding the company’s innovative contributions to metabolic health and weight management solutions, signaling a potentially transformative period for the firm as it progresses on its growth trajectory.

In an exciting development, Vyome Therapeutics, known for its focus on immuno-inflammatory and rare diseases, has announced its imminent public listing after securing approval from The Nasdaq Stock Market. The anticipated merger with ReShape is expected to be effective on August 15, 2025, and will see the company rebranded as Vyome Holdings, Inc., trading under the symbol “HIND.” Krishna Gupta, Chairman of Vyome, expressed enthusiasm about the approval, inviting RSLS shareholders to participate in this significant transition. Gupta emphasized that the company’s primary goal remains the creation of shareholder value while simultaneously driving innovation in the global healthcare landscape.

Vyome’s commitment is underscored by its dedication to addressing chronic inflammatory conditions affecting millions worldwide, with a market potential exceeding $100 billion. Shiladitya Sengupta, Vyome’s founder and an Associate Professor at Harvard Medical School, highlighted the company’s clinical-stage assets, which were developed over years of intensive research aimed at meeting critical health needs. As part of the merger preparation, ReShape’s Board of Directors also declared a 1-for-4 reverse stock split, set to enhance the post-merger ownership allocations for shareholders of both entities. As Vyome Therapeutics steps into this new era, it remains steadfast in its mission to improve patient lives and generate sustainable shareholder value.

Related news for (RSLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.